Danny Arends is an Associate Professor in Bioinformatics at Northumbria University, Department of Applied Sciences (Health & Life Sciences). He specializes in developing computational methods for quantitative trait locus (QTL) analysis, data visualization, and integration of large biological datasets. Prior to Northumbria, he held postdoctoral positions at Humboldt University in Berlin and completed his PhD in Bioinformatics at the University of Groningen (2014). Education: BSc in Lifescience & Technology, MSc in Molecular Biology, and PhD in Bioinformatics from the University of Groningen. Research focuses on creating open-source software tools such as R/qtl for QTL analysis, and contributions to platforms like MOLGENIS. His work integrates genomic, transcriptomic, and metabolic data to uncover genetic factors underlying complex traits like obesity, aging, and metabolic disorders. Teaching includes live-streamed lectures on R programming, bioinformatics, and data analysis on YouTube/Twitch. He also leads projects in computational biology, including the DaNode web server and HDDspeed tool for disk performance analysis. Key collaborations involve mouse models (e.g., Berlin Fat Mouse) and cattle genomics, with publications on genetic modulation of lifespan, gut microbiota responses to diets, and genomic loci influencing milk production in cattle.
Ling Hao is an Associate Professor in the Department of Chemistry and Biochemistry at the University of Maryland, specializing in Analytical Chemistry with a focus on Mass Spectrometry, Proteomics, Metabolomics, and their applications in Neurodegenerative Diseases and Cellular Biology. Their research integrates advanced mass spectrometry techniques with systems biology approaches to study lysosomal function, mitochondrial dynamics, and neuronal pathology. The HaoLabMS investigates molecular mechanisms underlying neurodegenerative disorders such as ALS and Alzheimer’s disease, emphasizing the role of protein quality control and metabolic pathways. Key research areas include: Development of novel quantitative proteomic and metabolomic methodologies Lysosome transport mechanisms in neurons Mitochondrial dysfunction in neurodegeneration Biomarker discovery for neurological diseases Proximity labeling proteomics for protein interaction mapping Recent work has focused on improving analytical workflows for multi-omics integration and contaminant removal, as well as characterizing lipid metabolic alterations in genetic neurodegenerative models. Their lab has pioneered methods like ContamSPOT and iDiLeu labeling for enhanced data reliability and metabolite quantification. Grant activities include NIH-funded projects on lysosomal biology and neuroprotection mechanisms. The lab collaborates with institutions globally to advance translational mass spectrometry applications in precision medicine and disease modeling. Lab activities: The HaoLabMS operates within the University of Maryland’s state-of-the-art proteomics facility, maintaining active collaborations across chemical, biomedical, and computational disciplines. Current projects include developing cross-platform normalization strategies for multi-omics data and exploring autophagy regulation in neuronal health.
Prof. Dr. Bernd Bodenmiller is a full Professor in Quantitative Biomedicine at the University of Zurich (UZH) and ETH Zurich. He leads the Department of Quantitative Biomedicine (DQBM) and holds a dual professorship between UZH and ETH. His research focuses on developing experimental and computational methods to study cancer biology at the single-cell level, particularly using imaging mass cytometry (IMC) to analyze tumor ecosystems. Education: Ph.D. in Systems Biology from ETH Zurich (2008) Postdoctoral training at ETH Zurich (2008-2009) and Stanford University (2009-2012) Research Interests: Bodenmiller’s lab investigates the regulatory systems governing cancer development, including tumor heterogeneity, immune interactions, and spatial organization of tumor cells. They pioneer technologies like IMC and 3D imaging to map cellular phenotypes and spatial networks in tumors. Key Contributions: The lab has developed tools such as the histoCAT software for IMC data analysis and contributed to understanding cancer-associated fibroblast heterogeneity. Their work bridges basic research with clinical applications, aiming to improve precision oncology through multi-omics approaches. Awards: Friedrich Miescher Prize (2019) ERC Consolidator Grant (2019)
Seppo Parkkila is a Professor and Dean at the Faculty of Medicine and Health Technology , University of Tampere. His research focuses on carbonic anhydrase enzymes, drug discovery for infectious diseases (e.g., tuberculosis, SARS-CoV-2), and bioinformatics-driven approaches to understand pathogen biology. He leads interdisciplinary projects integrating systems biology, pharmacology, and computational modeling to address global health challenges. Recent work includes vaccine development, antimicrobial resistance mechanisms, and therapeutic strategies for neurodegenerative and cardiovascular diseases. Key research themes include (1) carbonic anhydrase structure-function relationships, (2) development of multiomics tools for drug design (e.g., TFBSFootprinter), and (3) biomarker identification in cancer and neurological disorders. He has contributed to clinical trials evaluating therapies for keloid formation, post-COVID-19 recovery, and parasitic infections. His academic leadership role emphasizes innovation in biomedical education and translational research. Publications in 2024-2025 highlight advancements in: Bioinformatic analysis of SARS-CoV-2 entry mechanisms Machine learning approaches for chalcone drug discovery Systems biology modeling of tuberculosis pathogenesis Neuroprotective effects of carbonic anhydrase inhibitors Pharmacological strategies against protozoan pathogens
Fabian Braun is a medical researcher at the University Medical Center Hamburg-Eppendorf, affiliated with the Department of Medicine. His work focuses on kidney diseases, particularly Fabry disease and podocyte biology, with extensive publications in nephrology journals. He has made significant contributions to understanding renal pathology mechanisms and biomarker discovery. III. Department of Medicine, University Medical Center Hamburg-Eppendorf Active researcher with numerous publications from 2013-2025 ORCID: 0000-0002-4742-050X Dr. Braun's research primarily centers on molecular mechanisms underlying renal pathology in Fabry's disease, microvesicular signaling in renal health and disease, and the discovery of novel urinary microvesicular biomarkers. His work bridges basic science with clinical applications, particularly in understanding podocyte injury mechanisms and kidney disease progression. Analysis of his recent publications reveals a strong focus on kidney disease mechanisms, particularly Fabry nephropathy, podocyte biology, and extracellular vesicle research. His work has expanded to include studies on SARS-CoV-2 renal tropism and multi-organ involvement during the pandemic, demonstrating adaptability to emerging health challenges while maintaining focus on kidney pathophysiology. Dr. Braun has been involved in significant collaborative efforts, including the MISEV2023 guidelines for extracellular vesicle studies and the German Porphyria Registry. His research has appeared in high-impact journals including Nature Communications, Journal of Clinical Investigation, and Kidney International. As an active researcher, Dr. Braun has contributed to numerous collaborative projects and has been involved in advancing methodologies for kidney tissue analysis and biomarker discovery. His work with kidney organoids and multi-omics approaches represents cutting-edge research in nephrology. Dr. Braun is part of research teams focusing on kidney disease mechanisms, particularly within the Department of Medicine at University Medical Center Hamburg-Eppendorf, collaborating with international researchers on projects related to podocyte biology and kidney disease pathogenesis.
Matthias Dottermusch is a researcher at the Institute of Neuropathology, University Medical Center Hamburg-Eppendorf. His work spans neuro-oncology, epigenetics, and molecular pathology, focusing on brain tumors such as gliomas, medulloblastomas, and pituitary neuroendocrine tumors. He employs proteomic and epigenomic techniques to investigate tumor subtypes, therapeutic vulnerabilities, and diagnostic biomarkers. His recent publications highlight collaborations with interdisciplinary teams across neuroscience and oncology. Research Trends: Dottermusch's research integrates Molecular profiling of brain tumors Epigenetic analysis for classification Proteomic data harmonization tools Multiomic approaches to subtype-specific therapies
Prof. Dr. med. Julia Neumann is a faculty member at the Zentrum für Molekulare Neurobiologie Hamburg (ZMNH) within the Medical Faculty of the University Medical Center Hamburg-Eppendorf (UKE). She leads a research group focused on understanding the molecular mechanisms driving pediatric malignant brain tumors, particularly embryonal tumors with multilayered rosettes (ETMRs), atypical teratoid/rhabdoid tumors (ATRTs), and K27M-mutant midline gliomas. Research Interests: Her work combines in vitro and in vivo models to explore how developmental pathways like LIN28A overexpression contribute to tumorigenesis, with translational applications to human systems. Scientific Contributions: Key publications highlight advancements in proteomics , neural epigenetic signatures , and deep learning-based tumor classification . Awards & Memberships: Active member of the German Society for Neuropathology and Neuroanatomy (DGNN) since 2021, participating in professional societies and research networks.
Sören Lehmann is a Professor of Hematology at Uppsala University and leads a research group affiliated with Karolinska Institutet's Department of Medicine, Huddinge. His work focuses on acute myeloid leukemia (AML) through translational approaches integrating epigenetics, multiomic data, and drug sensitivity to improve precision medicine. Key collaborations include the Swedish AML Group , Nordic AML Group , and HOVON International Steering Committee . Specialist in Hematology and Internal Medicine PhD from Karolinska Institutet (2002) Postdoc at UCLA (2005-2006) Research spans epigenetic dysregulation in AML, long non-coding RNAs , clonal hematopoiesis , and therapy-related leukemias . His team employs CRISPR-Cas9 for functional validation and single-cell analyses to dissect heterogeneity. Recent projects include FLT3 mutation-targeted immunotherapy and HEAT-AML clinical trials . Publications emphasize multiomic integration for prognostic modeling, epigenetic drug targets , and real-world data applications in AML and APL. Funding includes the Swedish Cancer Foundation , Swedish Research Council , and Knut and Alice Wallenberg Foundation . His group trains PhD students including Elisabetta Cozzi and Louisa Fredrikson , with former members like Anne Neddermeyer . Collaborations span institutions including Uppsala University, Lund University, and RIKEN Institute (Japan).
Konstantinos Meletis is a Professor of Systems Neuroscience at the Department of Neuroscience, Karolinska Institutet . His research focuses on understanding neural circuit mechanisms underlying motivated behaviors and mood disorders, including the role of basal ganglia, hypothalamus, habenula, and serotonergic systems. His work integrates advanced technologies like optogenetics, spatial transcriptomics, and circuit mapping to dissect how neurons and circuits contribute to decision-making and pathological states. Key research areas include: Neural circuits regulating aversion and reward Dopamine pathways and Parkinson’s disease Genetic and molecular profiling of neuron types Optogenetic manipulation of brain circuits Awards and grants include the Arvid Carlsson Foundation Prize (2024), Swedish Research Council grants on striatal and dopamine circuits, and funding from the Knut and Alice Wallenberg Foundation. His lab has published extensively on spatial transcriptomics, striatal organization, and aversion circuits. Clinical and outreach efforts include public engagement through initiatives like the 'Adventure Through the Brain' project. His team collaborates on translational research, including studies on stress-related neurons and motor dysfunction in Parkinsonism.
Professor Miles Davenport is Program Head of the Infection Analytics Program at the Kirby Institute, University of New South Wales (UNSW). With a background spanning clinical medicine, experimental immunology, and mathematical modeling, he directs a team of applied mathematicians and evidence specialists focusing on host-pathogen interactions in SARS-CoV-2, HIV, and malaria. His work integrates experimental data with computational approaches to understand infection dynamics and immunity. His educational background includes: Bachelor of Science (Medicine) from University of Sydney MB BS (Medicine and Surgery) from University of Sydney D.Phil (Doctor of Philosophy) from University of Oxford Professor Davenport's research spans immunology, infectious diseases, and mathematical modeling. His team applies statistical and computational approaches to investigate treatment and immunity to infectious diseases, with major focuses on HIV immunity and latency, antimalarial treatment and immunity, and neonatal immunity. He has made significant contributions to understanding immune correlates for protection from SARS-CoV-2 infection, which has informed numerous guidelines on vaccination and treatment. His work bridges the gap between clinical medicine, immunology, and quantitative analysis, creating a unique interdisciplinary approach to infectious disease research. His recent publications demonstrate a strong focus on SARS-CoV-2 variants, vaccine effectiveness, HIV reservoir dynamics, and immune responses across different populations. The work spans mathematical modeling, clinical studies, and laboratory-based immunological investigations, reflecting his team's integrated approach to understanding host-pathogen interactions. There's a clear trend toward addressing emerging infectious disease threats through quantitative analysis of immune responses and transmission dynamics. Professor Davenport has held significant editorial positions including Senior Editor at eLife (2020-2024) and Editorial Board member at Journal of Virology (2015-2023). He served as President of the Australasian Society for Immunology (2009-2010), demonstrating leadership in the immunology community. He actively supervises postgraduate students, particularly seeking those with backgrounds in mathematics, statistics, or other quantitative disciplines to join his team. His Infection Analytics Program collaborates with approximately 30 experimental and clinical groups worldwide, using modeling to understand the dynamics of infection and immunity. Current thesis topics include Dynamics of HIV latency, Immunity to SARS-CoV-2, and Evidence Assessment in vaccine development. The Infection Analytics Program at the Kirby Institute serves as his primary research base, bringing together mathematicians, statisticians, and immunologists to tackle complex questions in infectious disease dynamics. The program's interdisciplinary approach allows for innovative solutions to challenges in vaccine development, treatment strategies, and understanding immune responses across different pathogens.
Dr Minh Ngoc Tran is a Researcher at the University of New South Wales (UNSW), affiliated with the Faculty of Medicine & Health Sciences. His work focuses on bioinformatics, health data science, and artificial intelligence applied to cancer research and molecular biology. Tran specializes in spatial analysis of cancer tissues, integrating single-cell sequencing with imaging to study tumor microenvironments and immune responses. His research also explores computational frameworks for multi-omics data and epigenetic mechanisms underlying aging and disease. Key areas of interest include colorectal cancer heterogeneity, SARS-CoV-2 pathogenesis, and translational bioinformatics for precision medicine. Tran's research employs advanced techniques such as spatial transcriptomics, multiplexed imaging mass cytometry, and AI-driven diagnostic models. His work bridges computational innovations with clinical relevance, particularly in oncology and infectious diseases. Recent projects include developing robust platforms for spatial multi-omics analysis and identifying early biomarkers for severe COVID-19 outcomes. While his articles emphasize cancer biology and immunology, they also highlight contributions to virology, epigenetics, and genomic technologies. Collaboration with interdisciplinary teams at UNSW and beyond drives his efforts to translate scientific discoveries into clinical applications.
Jiarui Ding is an Assistant Professor in the Department of Computer Science at the University of British Columbia , within the Faculty of Science. His research focuses on the intersection of bioinformatics, computational biology, and machine learning, with an emphasis on single-cell genomics and probabilistic deep learning. Key interests include computational immunology, cancer biology, and the application of AI to biomedical problems like food allergy neuroscience. He is affiliated with the CAIDA: UBC ICICS Centre for Artificial Intelligence Decision-making and Action and the Data Science Institute , indicating strong interdisciplinary engagement. He actively recruits doctoral students for research projects in these areas, with desired start dates year-round. His work bridges computational methods with biological systems, exemplified by publications on single-cell data integration ( e.g. , CellUntangler), generative models for T-cell receptors, and mechanistic studies of immune responses in diseases like eosinophilic esophagitis. His research also addresses challenges in multiomics data analysis and the development of novel algorithms for genomic data interpretation. No awards or grants are explicitly listed in the provided materials, though his involvement in high-impact projects suggests potential external funding. He emphasizes collaboration, stating availability for interdisciplinary projects and undergraduate research mentorship.
Professor Sejal Saglani is a leading academic in Paediatric Respiratory Medicine at Imperial College London's National Heart & Lung Institute (NHLI). She holds honorary consulting roles at the Royal Brompton Hospital and chairs the European Respiratory Society's Paediatric Asthma and Allergy Group. Her research focuses on early-life mechanisms of asthma and preschool wheeze, integrating clinical and translational approaches. Education: MBBS from University of Leicester, postgraduate asthma research fellowship at NHLI, and Wellcome Intermediate Clinical Fellowship. She has secured grants from MRC, NIHR, and Wellcome Trust. Awards include the ERS Romain Pauwels Award (2015) and Young Investigator Award (2009). Research Interests: Mechanisms of asthma onset in early childhood, biomarker-driven therapies, airway remodelling, and microbiome influences. Her lab uses neonatal mouse models and human airway samples to bridge preclinical and clinical studies, with direct application to clinical trials like the TREAT trial comparing mepolizumab and omalizumab. Grants & Awards: NIHR Career Development Fellowship (2015), MRC New Investigator Award (2012), Wellcome Trust support (2008), and British Lung Foundation Fellowship (2007). She also holds editorial roles at Clinical and Experimental Allergy . Labs & Affiliations: Leads the Paediatric Severe Asthma Group within the Inflammation, Repair and Development Section. Collaborates with the Lloyd Lab and Imperial NHLI teams. Active in the Immuno-Pathology Network and Microbiome Network. Her work emphasizes translational research, including contactless monitoring devices (e.g., Albus Home) and telehealth interventions for asthma management.
Paul Clement is a Professor and Department Chair at the KU Leuven Faculty of Medicine , leading the Department of Oncology . His research spans neuro-oncology, head and neck cancer, and precision medicine, with expertise in immunotherapy, radiation therapy, and translational oncology. Projects focus on brain tumor biology, early cancer detection in TP53 mutation carriers, and data-driven precision oncology platforms. Recent publications emphasize glioma therapy outcomes, meningioma resistance mechanisms, and single-cell multiomics for personalized treatment. His work integrates clinical trials (e.g., INTERLINK-1, CATNON trial) with advanced imaging/radiation toxicity studies and cfDNA analysis. Teaching roles include courses in medical oncology, hemato-oncology, and clinical reasoning.
Dr. Jacob Siedlik is an Associate Professor in the Department of Biology at the Hal Marcus College of Science and Engineering, University of West Florida. His research integrates computational biology, multiomics data analysis, and advanced statistical modeling to address questions in exercise physiology, human performance, and clinical health. He applies Bayesian methodologies to model immune responses and physiological variability in human subjects. Research Interests: Dr. Siedlik's work focuses on leveraging metabolomic, lipidomic, and proteomic data to understand biological responses under stress, including athletic performance, chemotherapy side effects, and military challenges. His lab develops statistical models to quantify variability and improve clinical decision-making. Key areas include immune response modeling, omics integration, and data-driven biomedical research. The recent publications highlight a strong trend in interdisciplinary research combining nutrition, exercise science, and clinical outcomes. His work spans elite athletes, cancer models, spinal cord injury, and neurodevelopmental genetics, demonstrating a broad application of computational and statistical approaches in biomedicine. Scientific Contributions: Advancing Bayesian methods in human physiology Investigating ketone and creatine supplementation in performance and disease Exploring metabolic and inflammatory responses to extreme physical stress Contributing to large-scale genetic studies in neurodevelopment Advising and Grants: While specific students and funded grants are not listed, Dr. Siedlik is actively involved in collaborative research across institutions, contributing to multi-author studies in high-impact journals. His work suggests engagement in interdisciplinary teams and potential external funding in exercise science, rehabilitation, and biomedical data analytics. Laboratory and Teams: His lab focuses on computational modeling of immune and physiological responses. He collaborates with researchers in sports science, oncology, neuroscience, and public health, indicating a highly integrated research environment focused on translational outcomes.
